Select Medical Holdings Corp to be Acquired for $16.50/Share in Definitive Merger Agreement

summarizeSummary

Select Medical Holdings Corp announced a definitive merger agreement to be acquired for $16.50 per share in cash, a thesis-altering event that overshadows its mixed Q1 2026 financial results.

check_boxKey Events

• Definitive Merger Agreement Signed

  The company entered into a definitive agreement on March 2, 2026, to be acquired by a consortium led by its Executive Chairman and Senior Executive Vice President for $16.50 per share in cash. This take-private transaction will result in the company's delisting from the NYSE.

• Merger Conditions and Timeline

  The acquisition is subject to regulatory approvals, including the expiration of the Hart-Scott-Rodino waiting period on April 27, 2026, and stockholder approval. The merger is expected to close in mid-2026 and has no financing condition.

• Mixed Q1 2026 Financial Results

  For the first quarter ended March 31, 2026, revenue increased 5.0% to $1,421.5 million, but net income decreased 14.7% to $63.8 million, and Adjusted EBITDA declined 6.5% to $141.6 million. Diluted EPS was $0.35, down from $0.44 in the prior year.

• 2026 Business Outlook Maintained

  Despite mixed Q1 results, the company is maintaining its full-year 2026 business outlook, projecting revenue between $5.6 billion and $5.8 billion, and Adjusted EBITDA between $520.0 million and $540.0 million.

auto_awesomeAnalysis

Select Medical Holdings Corporation has entered into a definitive merger agreement to be acquired by a consortium led by its Executive Chairman and Senior Executive Vice President for $16.50 per share in cash. This take-private transaction, initially proposed on March 2, 2026, represents a fundamental change in the company's future, leading to its delisting from the NYSE upon completion. The deal is subject to regulatory and stockholder approvals, with the Hart-Scott-Rodino waiting period already expired. Concurrently, the company reported mixed first-quarter 2026 financial results, with revenue increasing but profitability metrics declining year-over-year, though it maintained its full-year 2026 business outlook. The deferral of equity award vesting for the Executive Chairman and Senior Executive Vice President, contingent on continued service, aligns executive incentives with the successful completion of the merger and ongoing operations.